spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.

Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.

 

For further information please contact:

Advertising
Jonathan Smith

Editorial
Charlie Burgon

We're also on Twitter! Follow us @EPCmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


View the digital version of EPC




 

epc
 
 
Featured in this issue
Clinical Development
505(b)(2) Pathway

Beyond the Cliff

Ken Phelps at Camargo Pharmaceutical Services offers a solution to the pharma cliff in the form of the FDA’s 505(b)(2) pathway. As the amount of drugs going off-patent diminishes, this route to approval can help generic companies boost revenue.





The introduction
Editor’s Letter

Graham Hughes homes in on the theme of patient protection in this issue, and discusses the features that have a regional focus.
  Legal & Regulatory
Vulnerable Populations

Patient Protection

Investigators' main priority should be ensuring the safety of patients, especially those in vulnerable populations. Theorem Clinical Research's Marc Hoffman summarises the stringent measures required to guard those who are most at risk.


 

spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December

Banner of ESMO.EPC on Samedan
Banner of Inform.EPC on Samedan
 
Industry Events

InForm Europe

17-18 November 2015, Hilton Barcelona, Barcelona

InForm Europe 2015 is the leading pharma event for decision makers working in formulation and pre formulation across Europe, that meets the needs of an industry that is set to rise to $224 billion in 2017
More info >>

 
News and Press Releases

Further Expansion and New Appointments for ClinTec

ClinTec International has announced a Regional Hub Office for Sub-Saharan Africa, with the opening of new, larger offices in Johannesburg, South Africa.
More info >>

Banner of Drug Delivery Congress on Samedan
air transport logo

 

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement